Specifically, the ERK1/2-WTAP-dependent m6A methylation modification enhances the stability of ENO1 and its glycolytic activity, thereby providing metabolic support for the proliferation and metastasis of breast cancer cells (Ou et al., 2021). Here, ENO1 is linked to breast carcinoma.